|Medtronic Supports CMS Ruling on TAVR National Coverage Determination|
DUBLIN - June 21, 2019 - Medtronic plc (NYSE:MDT) today issued the following statement regarding the final decision memo updating the TAVR National Coverage Determination (NCD) 20.32 announced by the Centers for Medicare & Medicaid Services (CMS):
As a global leader in heart valve therapies, Medtronic is committed to delivering meaningful, evidence-based products and therapies across the care continuum that provide excellent outcomes for heart valve patients across the globe. Today's decision underscores the importance of high-quality evidence in shaping coverage policy and beneficiary access to life-saving therapies.
Medtronic supports the updated TAVR NCD and believes the new coverage policy allows for appropriate patient access to TAVR - especially for patients in rural communities - while still maintaining rigorous requirements for centers and operators providing the therapy.
Medtronic has been an active participant over the past year during the National Coverage Analysis (NCA) and its public commenting periods and provided several recommendations to support patients continuing to have sufficient access to TAVR therapy. We are pleased to see that today's decision is consistent with our position.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.